Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAntonio Leidi

About this trial

The goal of this clinical trial is to investigate whether a lung ultrasonography (LUS)-guided decongestion strategy in adults hospitalized for acute heart failure (AHF) can improve patient-centered outcomes.

The main questions it aims to answer are:

* Does this strategy shorten the length of stay and reduce early hospital readmissions? * Does this strategy improve patients' symptoms and quality of life ?

Researchers will compare LUS to physical examination (PE).

Eligibility criteria

Qualifiers

≥ 18 years old

Planned or actual admission to intermediate care units, general internal medical or cardiology wards

Diagnosis of congestive AHF on admission chart (primary or secondary diagnosis)

Raised value of N terminal-pro-brain natriuretic peptide (≥1000 ng/l).

Disqualifiers

Known isolated right heart failure

Systolic blood pressure <90 mmHg, mean arterial pressure <65 mmHg at the moment of inclusion

The following conditions mimicking lung cardiogenic oedema on LUS if known at inclusion and documented: Interstitial lung disease, lung cancer or metastasis, acute respiratory distress syndrome, pulmonary contusion

Known virologically confirmed SARS-CoV-2 pneumonia in the preceding 3 months

Trial design

Treatments tested in this trial

  • LUS decongestive strategy
  • PE decongestive strategy

Treatment groups

222 Participants
are divided into 2 treatment groups

Locations

5
Geneva University Hospitals1205, GenevaCanton of Geneva, Switzerland
Trois-Chêne Hospital, Geneva Univesity Hospitals1204, GenevaCanton of Geneva, Switzerland
Inselspital, Universitätspital BernSwitzerland, Switzerland
Fribourg University Hospital Fribourg Switzerland

Sponsors and collaborators

Antonio Leidi

Lead sponsor

University Hospital, Geneva

Sponsor institution

University Hospital, Geneva

Collaborator